【摘要】：目的觀察補(bǔ)體調(diào)節(jié)蛋白CD59、腫瘤增殖抗原Ki67和抑癌基因P16在胰腺癌組織中的表達(dá)情況,分析三者與胰腺癌TNM分期、病理分化等的相關(guān)性,為胰腺癌發(fā)生的分子機(jī)制、診斷與治療提供實(shí)驗(yàn)依據(jù)。方法選取40例胰腺癌組織標(biāo)本,另選35例手術(shù)切除的胰腺癌旁組織,應(yīng)用免疫組化(S-P)法,檢測(cè)胰腺癌組和胰腺癌旁組中CD59、Ki67與P16基因的表達(dá),以PBS液代替一抗作為陰性對(duì)照,選已知陽(yáng)性切片作為陽(yáng)性結(jié)果對(duì)照,將胰腺癌組織與胰腺癌旁組織染色,統(tǒng)一評(píng)分標(biāo)準(zhǔn)進(jìn)行結(jié)果比較,觀察兩組中CD59、Ki67與P16的表達(dá)情況,所有數(shù)據(jù)經(jīng)統(tǒng)計(jì)學(xué)軟件SPSS22.0處理后進(jìn)行統(tǒng)計(jì)。結(jié)果在40例胰腺癌組織標(biāo)本中,CD59陽(yáng)性表達(dá)率65%;Ki67的陽(yáng)性表達(dá)率77.5%;P16陽(yáng)性表達(dá)率42.5%。癌旁對(duì)照組中,CD59陽(yáng)性表達(dá)率34.29%;Ki67陽(yáng)性表達(dá)率51.43%;P16陽(yáng)性表達(dá)率88.57%。胰腺癌組中CD59、Ki67的陽(yáng)性表達(dá)率較正常對(duì)照組明顯升高;相反,胰腺癌組中P16陽(yáng)性表達(dá)率低于癌旁對(duì)照組。CD59、Ki67、P16在胰腺癌組與癌旁對(duì)照組的表達(dá)差異均有顯著統(tǒng)計(jì)學(xué)意義,P0.05。胰腺癌的腫瘤分化程度和臨床分期、附近淋巴結(jié)轉(zhuǎn)移、遠(yuǎn)處轉(zhuǎn)移各組間與CD59和Ki67表達(dá)強(qiáng)度的比較,差異均有統(tǒng)計(jì)學(xué)意義,P0.05。即低分化型胰腺癌組中CD59、Ki67的表達(dá)強(qiáng)度高于高、中分化組;Ⅲ+Ⅳ期組CD59、Ki67表達(dá)強(qiáng)度高于Ⅰ+Ⅱ期組;發(fā)生附近淋巴結(jié)與遠(yuǎn)處轉(zhuǎn)移組中CD59、Ki67的表達(dá)高于未轉(zhuǎn)移組。胰腺癌的分化程度和臨床分期、附近淋巴結(jié)轉(zhuǎn)移各組間與P16表達(dá)強(qiáng)度的比較均有統(tǒng)計(jì)學(xué)意義,P0.05,發(fā)生遠(yuǎn)處轉(zhuǎn)移組中P16表達(dá)無(wú)明顯意義P=0.05。高、中分化型胰腺癌組中P16的表達(dá)強(qiáng)度高于低分化組;Ⅲ+Ⅳ期組中P16表達(dá)強(qiáng)度高于Ⅰ+Ⅱ期組;發(fā)生附近淋巴結(jié)組中Ki67表達(dá)高于未轉(zhuǎn)移組。胰腺癌的分化程度、臨床分期、附近淋巴結(jié)轉(zhuǎn)移、遠(yuǎn)處轉(zhuǎn)移與CD59表達(dá)均呈正相關(guān),P0.05,r值分別為:0.643,0.564,0.598,0.443;而年齡、性別與CD59表達(dá)強(qiáng)度間均無(wú)明顯相關(guān),P0.05;胰腺癌的分化程度、臨床分期、附近淋巴轉(zhuǎn)移、遠(yuǎn)處轉(zhuǎn)移與Ki67表達(dá)均呈正相關(guān),P0.05,r值分別為:0.670,0.652,0.734,0.518;年齡、性別與Ki67無(wú)相關(guān)性,P0.05;胰腺癌的分化程度、臨床分期、附近淋巴轉(zhuǎn)移、遠(yuǎn)處轉(zhuǎn)移與P16表達(dá)均呈負(fù)相關(guān),P0.05,r值分別為:-0.673,-0.387,-0.551,-0.315,年齡、性別與P16表達(dá)無(wú)相關(guān)性,P0.05。胰腺癌組中CD59與Ki67存在正相關(guān),P0.05,r=0.734;CD59與P16存在負(fù)相關(guān),P0.05,r=-0.580;Ki67與P16存在負(fù)相關(guān),P0.05,r值-0.553。結(jié)論CD59、Ki67高表達(dá)與胰腺癌的分化程度、臨床分期、淋巴結(jié)轉(zhuǎn)移有關(guān),可能成為胰腺癌早期診斷的參考指標(biāo)之一。P16在胰腺癌組織中表達(dá)降低,且與胰腺癌分化程度、臨床分期呈負(fù)相關(guān),尤其晚期患者更為顯著,故P16可以作為診斷胰腺癌晚期的提示信號(hào)。CD59在胰腺癌組織中表達(dá)升高,而且CD59有可能成為胰腺癌預(yù)后及靶向治療的重要分子靶標(biāo)。
[Abstract]:Objective to investigate the expression of complement regulated protein CD59, (CD59,) tumor proliferating antigen (Ki67) and tumor suppressor gene P16 (P16) in pancreatic carcinoma, and to analyze the relationship between them and TNM stage and pathological differentiation of pancreatic carcinoma, which may be the molecular mechanism of pancreatic carcinoma. Diagnosis and treatment provide experimental basis. Methods the expression of CD59,Ki67 and P16 genes in pancreatic carcinoma and paracancreatic tissues were detected by immunohistochemistry (S-P) in 40 cases of pancreatic carcinoma and 35 cases of paracancreatic tissues. Using PBS solution instead of first antibody as negative control and known positive sections as positive result control, the tissues of pancreatic cancer and adjacent tissues of pancreatic cancer were stained, and the results were compared according to the unified scoring criteria. The expression of CD59,Ki67 and P16 in the two groups was observed. All the data were processed by statistical software SPSS22.0. Results in 40 cases of pancreatic carcinoma, the positive expression rate of CD59 was 65.The positive rate of P16 was 77.5% and the positive rate of P16 was 42.5%. In the paracancerous control group, the positive expression rate of CD59 was 34.29% and the positive rate of P16 was 51.43% and 88.57%. The positive expression rate of CD59,Ki67 in pancreatic cancer group was significantly higher than that in normal control group. On the contrary, the positive expression rate of P16 in pancreatic cancer group was lower than that in paracancerous control group. There was significant difference in expression of CD59,Ki67,P16 between pancreatic cancer group and paracancerous control group (P0.05). There were significant differences in tumor differentiation and clinical stage, lymph node metastasis and distant metastasis with CD59 and Ki67 expression in all groups (P 0.05). The expression of CD59,Ki67 in poorly differentiated pancreatic carcinoma group was higher than that in moderately differentiated group, the expression of CD59,Ki67 in stage 鈪，

本文編號(hào)：2354011